Manas AI, a synthetic intelligence-driven drug discovery startup, has secured $24.6 million in seed funding led by Reid Hoffman, Basic Catalyst, and Greylock Companions. Initially, the corporate goals to concentrate on growing therapies for breast most cancers, prostate most cancers, and lymphoma.
“We’re nearer than we’ve ever been. Right now, we announce the launch of Manas AI, and getting down to shift drug discovery from a decade-long course of to 1 that takes a couple of years, bringing life-saving therapies to sufferers years quicker than ever,” Hoffman additional mentioned on Linkedin.
In response to him, the funding might be used to hurry up drug discovery, decreasing improvement time from 10 years to only a few years. Manas AI will use AI to analyse molecules 100 occasions quicker than conventional strategies, which is able to assist researchers discover extra potentialities in much less time. The funding may even assist collaboration with prime scientists, together with Nobel laureates and Nationwide Academy members, to speed up the seek for new therapies.
Whereas Manas AI’s funding is modest in comparison with different AI biotech startups, it goals to design new molecules utilizing AI and take a look at them in moist labs. In distinction, Xaira Therapeutics, one other AI drug discovery startup, launched final 12 months with $1 billion in funding, whereas Treeline Biosciences raised $422 million.
Manas AI will use Microsoft Azure for cloud computing and leverage Microsoft’s AI experience to speed up drug improvement. Hoffman’s hyperlinks to Microsoft are properly established, with the tech big buying LinkedIn in 2016. The announcement was made throughout a presentation for his newest e-book, ‘Superagency: What May Probably Go Proper with Our AI Future’.
Regardless of having much less funding than its opponents, Manas AI goals to make a significant affect in AI-driven medication, specializing in precision-designed molecules for most cancers therapy.
The submit Reid Hoffman’s Manas AI Raises $24.6 Million appeared first on Analytics India Journal.